



Final Appraisal Recommendation
Advice No: 4115 – December 2015

Atazanavir/cobicistat (Evotaz[®]▼) 300 mg/150 mg film-coated tablets

**Limited submission by Bristol-Myers Squibb
Pharmaceuticals Ltd**

Recommendation of AWMSG

Atazanavir/cobicistat (Evotaz[®]▼) in combination with other antiretroviral medicinal products is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2629), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Bristol-Myers Squibb Pharmaceuticals Ltd
Date of first issue	December 2015
Last reviewed	March 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 4115: atazanavir/cobicistat (Evotaz[®]▼) 300 mg/150 mg film-coated tablets. December 2015.

